

Through In Vitro Gametogenesis — Young Stem Cells

Jaba Tkemaladze

E-mail: itkemaladze@longevity.ge

Citation: Tkemaladze, J. (2025). Through In Vitro Gametogenesis — Young Stem Cells. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.1587313>

Abstract

In vitro gametogenesis (IVG) represents a groundbreaking technology that opens new horizons in reproductive and regenerative medicine. Recent advancements enable the direct reprogramming of somatic cells into germline cells, bypassing the pluripotency stage, which reduces the risk of genetic abnormalities and accelerates the process. The key stages of IVG include the induction of primordial germ cell-like cells (PGCLCs), differentiation into mature gametes, and the formation of functional germ cells under controlled conditions. The primary signaling pathways involved in this process are BMP, WNT, and retinoic acid, which regulate initiation, proliferation, and meiotic entry. To accurately replicate the gonadal microenvironment, researchers employ 3D cultures, organoid systems, and microfluidic devices. Despite significant progress, the efficiency and quality of in vitro-derived gametes still fall short of their natural counterparts. Future developments in this technology hinge on optimizing differentiation protocols, leveraging

single-cell technologies, integrating genome editing, and establishing international standards. Additionally, IVG holds promise for systemic rejuvenation by replacing aged stem cells with young ones derived from reprogrammed cells. Ethical and regulatory concerns remain pressing, particularly regarding artificial embryo creation and potential social inequalities. IVG has the potential to become a cornerstone technology in treating aging, extending healthy lifespan, addressing age-related diseases, and overcoming infertility.

Keywords: Gametogenesis, In Vitro, Stem Cells, Centrioles, Reprogramming, Reproduction, Rejuvenation.

Introduction

In vitro gametogenesis (IVG) is the process of generating functional germ cells (gametes) from somatic or pluripotent stem cells under laboratory conditions. This technology represents a revolutionary breakthrough in reproductive biology and medicine, offering novel solutions for infertility treatment, fertility preservation,

genetic correction of hereditary disorders, and even enabling genetically related offspring for same-sex couples and single individuals (Weselich V. G. et al., 2023).

Over recent decades, advances in cell biology, molecular genetics, and bioengineering have significantly enhanced our understanding of gametogenesis mechanisms and the development of methods to replicate it in vitro. However, despite substantial progress in experiments using model organisms (primarily mice), applying IVG in humans remains a complex challenge, requiring the overcoming of numerous scientific, technical, and ethical barriers (Yoshimatsu, S. et al., 2022; Cho, I. K., & Easley, C. A., 2023).

The primary motivation driving IVG development is the limitations of existing assisted reproductive technologies (ART). Conventional approaches, such as in vitro fertilization (IVF) and gamete cryopreservation, fail to address absolute infertility in patients lacking functional germ cells (e.g., due to chemotherapy or radiation therapy). Furthermore, current methods cannot counteract age-related fertility decline in women, which is linked to ovarian reserve depletion (Romualdez-Tan M. V., 2023).

Modern research in cellular aging and reproductive technologies offers new avenues to overcome fundamental biological constraints associated with age-related changes. One critical issue in aging is the selective accumulation of aged centrioles in stem cells, leading to the gradual degradation of their proliferative potential and functional activity (Basto et al., 2008; Loncarek & Bettencourt-Dias, 2018). Centrioles play a pivotal role in cytoskeleton


organization, cell cycle regulation, and genetic stability maintenance, and their dysfunction is linked to age-related diseases, including cancer and neurodegenerative disorders (Nigg & Holland, 2018; Fong et al., 2016).

A particularly promising solution to this problem lies in in vitro gametogenesis (IVG)—a technology that enables the generation of functional gametes from somatic or pluripotent stem cells under controlled laboratory conditions (Hayashi et al., 2012; Saitou & Miyauchi, 2016). IVG opens the possibility of creating personalized stem cells with rejuvenated centrioles, potentially compensating for age-related impairments in reproductive and regenerative medicine (Clark et al., 2021; Yoshino et al., 2021).

Centrioles and Their Role in Aging

Centrioles are essential components of the centrosome, participating in spindle organization, cell polarity maintenance, and cell cycle regulation (Bettencourt-Dias & Glover, 2007; Arquint & Nigg, 2016). They are known as non-reparable organelles—meaning entropy-induced damage cannot be repaired. In stem cells, centrioles are distributed asymmetrically: one daughter cell retains stemness properties and inherits "old" centrioles, leading to progressive damage accumulation and diminished regenerative potential (Anderson & Stearns, 2009; Wang et al., 2020). This process, termed centriolar drift, is considered a key factor limiting cellular proliferative capacity and contributing to age-associated diseases (Loncarek & Khodjakov, 2009; Wong et al., 2015).

Figure 1. Selective distribution of structures and molecules is characteristic of both prokaryotes and eukaryotes.



Interestingly, the selective inheritance of aged centrioles occurs alongside the selective distribution of other young structures and molecules.

IVG as a Tool for Centriolar Renewal

In vitro gametogenesis circumvents natural limitations imposed by aged centriole accumulation through:

- Reprogramming somatic cells into a pluripotent state, which is accompanied by centrosome renewal (Takahashi & Yamanaka, 2006; Buganim et al., 2013).
- Generating primordial germ cell-like cells (PGCLCs) that form new, damage-free centrioles during differentiation (Hayashi et al., 2011; Ishikura et al., 2021).
- Epigenome editing to eliminate errors accumulated during aging (Hanna et al., 2009; Hikabe et al., 2016).

Moreover, IVG enables the creation of autologous stem cells with rejuvenated centrosomes, which is particularly valuable for patients with age-related infertility or those who have undergone gonadotoxic cancer therapies (Yamashiro et al., 2018; Murakami et al., 2021).

Overcoming Chromosomal Conjugation Restrictions

A major limitation of conventional cell therapies is the risk of immune rejection due to transplant incompatibility (Dahl et al., 2016). IVG addresses this issue by producing gametes and derived stem cells with identical histocompatibility systems, eliminating the need for immunosuppression (Sugimoto et al., 2015; von Kopylow et al., 2020).

Prospects

Despite its immense potential, IVG faces several scientific and ethical challenges:

- Epigenetic instability in artificially derived gametes (Saitou & Yamaji, 2012; Kobayashi et al., 2017).
- Risk of oncogenic transformation during prolonged stem cell culture (Baker et al., 2016; Yamashiro et al., 2020).
- Ethical concerns surrounding artificial gamete creation and germline editing (Ishii et al., 2015; Mathews et al., 2017).

IVG is a transformative technology capable of overcoming fundamental aging-related limitations. The ability to generate stem cells with renewed centrioles and full histocompatibility opens new frontiers in regenerative medicine and healthy lifespan extension (Hikabe et al., 2021; Saitou & Hayashi, 2022). However, clinical

implementation requires further exploration of IVG's molecular mechanisms and the establishment of international ethical guidelines (Hyun et al., 2016; Pera et al., 2020).

Current State of Research in In Vitro Gametogenesis (IVG)

Key Stages of In Vitro Gametogenesis

In vitro gametogenesis (IVG) represents an intricate multi-stage process that requires precise replication of key germ cell developmental stages under laboratory conditions. Contemporary research has identified four critical phases of this process, each presenting unique technological challenges and requiring specific culture conditions.

Derivation of Pluripotent Stem Cells (PSCs)

The starting material for IVG consists of pluripotent stem cells, which can be obtained from two primary sources:

1. Embryonic stem cells (ESCs) isolated from the inner cell mass of blastocysts (Takahashi & Yamanaka, 2006)
2. Induced pluripotent stem cells (iPSCs) generated through somatic cell reprogramming (e.g., skin fibroblasts) using Yamanaka factors (OCT4, SOX2, KLF4, c-MYC) (Buganim et al., 2013)

A significant breakthrough in recent years has been the development of methods for

direct somatic-to-germline reprogramming that bypass the pluripotency stage (Hayashi et al., 2011). This approach reduces culture time and minimizes the risk of genetic abnormality accumulation.

Differentiation into Primordial Germ Cell-Like Cells (PGCLCs)

The pivotal stage of IVG involves the induction of PGC-like cells (PGCLCs), which requires accurate replication of the embryonic microenvironment. Recent studies have identified the crucial involvement of several signaling pathways:

- BMP (bone morphogenetic protein): Plays a central role in gametogenesis initiation (Saitou & Hayashi, 2022)
- WNT: Maintains PGCLC proliferation (Ishikura et al., 2021)
- Retinoic acid (RA): Essential for meiotic entry (Yoshino et al., 2021)

Epigenetic reprogramming of PGCLCs presents particular challenges, as it requires global DNA demethylation and proper imprinting mark establishment (Hikabe et al., 2016). Recent studies demonstrate that BMP signaling attenuates the MAPK/ERK pathway and reduces DNA methyltransferase (DNMT) activity, facilitating epigenetic remodeling (Saitou & Miyauchi, 2016).

Formation of Oogonia and Spermatogonia

Further differentiation of PGCLCs into mature gamete precursors depends on sex determination:

- In males, this process is regulated by SRY and SOX9 genes (Kobayashi et al., 2017)

- In females, FOXL2 and RSPO1 play key roles (Murakami et al., 2021)

Current protocols can generate mitotic pro-spermatogonia and oogonia capable of exponential in vitro amplification (over 10 billion-fold) (Clark et al., 2021). However, the efficiency remains low (5-10%), necessitating further optimization of culture conditions.

Oocyte and Sperm Maturation

The most challenging stage involves meiotic completion and functional gamete formation, requiring:

- Precise replication of gonadal niche microenvironments (Hayashi et al., 2012)
- Interaction with somatic cells (granulosa cells in females, Sertoli cells in males) (Yamashiro et al., 2018)
- Proper meiotic spindle organization and chromosome segregation (Nigg & Holland, 2018)

To address these challenges, researchers are developing:

- 3D cultures mimicking gonadal structures (Hikabe et al., 2021)
- Stem cell-derived organoid systems (Ishikura et al., 2021)
- Microfluidic devices for microenvironment control (Yoshino et al., 2021)

Despite significant progress, in vitro mature gamete production efficiency remains low, and quality often falls short of natural counterparts (Saitou & Hayashi, 2022). This stems from difficulties in replicating complex spatiotemporal signaling molecule and hormone patterns in culture.

Key Achievements and Future Directions

Since 2012, major IVG milestones include:

- Generation of functional mouse gametes from iPSCs yielding healthy offspring (Hayashi et al., 2012)
- Development of PGCLC epigenetic reprogramming methods (Saitou & Miyauchi, 2016)
- Creation of first human oogonia and spermatogonia prototypes (Yamashiro et al., 2018)
- Advancement of organoid technologies for gonadal niche modeling (Hikabe et al., 2021)

However, clinical translation requires addressing several challenges:

- Low differentiation efficiency (Kobayashi et al., 2017)
- Epigenetic abnormalities in artificial gametes (Saitou & Yamaji, 2012)
- Oncogenic transformation risk during prolonged culture (Baker et al., 2016)
- Ethical concerns regarding artificial gamete creation (Hyun et al., 2016)

Promising research directions include:

- Differentiation protocol optimization using single-cell technologies
- Development of personalized organoid systems
- IVG integration with genome editing tools
- Establishment of international quality and safety standards

In Vitro Gametogenesis (IVG) Technologies and Methods: Current Approaches and Future Perspectives

Application of Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (iPSCs) have revolutionized IVG research through their unique capacity to differentiate into any cell type, including germ cells (Takahashi & Yamanaka, 2006). The iPSC technology, first described by Yamanaka and colleagues, relies on somatic cell reprogramming (e.g., skin fibroblasts) using four core transcription factors: OCT4, SOX2, KLF4, and c-MYC (Buganim et al., 2013).

Key advantages of iPSCs for IVG:

- Material accessibility: Can be derived from various somatic tissues (skin, blood, urine) (Hayashi et al., 2011)
- Personalized approach: Enables autologous gamete production with matching histocompatibility (Yamashiro et al., 2018)
- Ethical acceptability: Avoids embryonic stem cell use, addressing ethical concerns (Saitou & Hayashi, 2022)

However, iPSC applications in IVG face technical limitations. Somatic cell reprogramming efficiency remains relatively low (typically 0.1-1%), and resulting cells

may retain epigenetic memory of source tissue (Clark et al., 2021). Moreover, extended iPSC culture increases genetic abnormality risks, particularly problematic for gamete generation (Baker et al., 2016).

Critical Signaling Pathways in IVG

BMP Signaling

The BMP (bone morphogenetic protein) pathway plays a central role in primordial germ cell (PGC) induction in vitro. Studies demonstrate that BMP4 activates expression of key transcription factors BLIMP1, PRDM14, and TFAP2C, essential for PGCLC specification (Saitou & Miyauchi, 2016). Notably, BMP signaling suppresses the MAPK/ERK pathway, reducing DNA methyltransferase (DNMT) activity and facilitating epigenetic remodeling crucial for proper germ cell development (Ishikura et al., 2021).

Retinoic Acid (RA)

Retinoic acid serves as a key meiosis regulator in oogenesis. Mouse studies show RA induces expression of Stra8 and Rec8 genes required for oogonia meiotic entry (Yoshino et al., 2021). Interestingly, unlike constant testicular RA presence in males, ovarian production occurs cyclically, explaining asynchronous oocyte meiotic entry (Hikabe et al., 2016).

GDF9 and BMP15

These oocyte-specific growth factors critically influence in vitro folliculogenesis. GDF9 (growth differentiation factor 9) and BMP15 (bone morphogenetic protein 15) are secreted by oocytes, regulating

surrounding granulosa cell proliferation and differentiation (Murakami et al., 2021). Studies demonstrate that adding recombinant GDF9 and BMP15 to culture media significantly improves *in vitro* oocyte maturation, increasing the percentage reaching metaphase II (Kobayashi et al., 2017).

Modeling the Gonadal Microenvironment

Three-Dimensional (3D) Culture Systems

Conventional two-dimensional (2D) monolayer cultures fail to adequately replicate the intricate three-dimensional microenvironment of gonadal tissues, significantly limiting their applicability in IVG research (Yoshino et al., 2021). In stark contrast, advanced 3D culture systems enable cells to interact in all three spatial dimensions, thereby providing a far more physiologically relevant approximation of *in vivo* conditions (Hikabe et al., 2021). The principal types of 3D culture platforms employed in IVG studies include:

1. Spheroids: Self-organizing cellular aggregates that form spontaneously under low-adhesion conditions, mimicking early embryonic development (Hayashi et al., 2012)
2. Hydrogel-based systems: Utilizing either natural biopolymers (collagen, fibrin) or synthetic polymers to recreate key aspects of the native extracellular matrix (Yamashiro et al., 2018)
3. Rotating wall vessel bioreactors: Specialized devices that maintain optimal gas exchange and nutrient

delivery for large-scale cellular aggregates (Saitou & Hayashi, 2022)

Within IVG research, 3D cultures prove particularly valuable for recapitulating the dynamic interplay between germ cells and their supporting somatic cells. For instance, co-culturing PGCLCs with granulosa cells within a 3D collagen matrix has been shown to dramatically enhance the efficiency of *in vitro* oocyte differentiation (Ishikura et al., 2021).

Organoid Culture Systems

Organoids represent miniature, simplified versions of organs that can be generated *in vitro* from stem cells, exhibiting remarkable architectural and functional complexity (Clark et al., 2021). In the context of IVG, ovarian and testicular organoids have attracted particular interest due to their potential to provide the necessary niche conditions for complete gamete maturation (Murakami et al., 2021). Recent breakthroughs in gonadal organoid development include:

- Japanese researchers have pioneered methods for generating ovarian organoids from iPSCs containing all major ovarian cell types, including granulosa and theca cells (Hikabe et al., 2021)
- In 2024, scientists demonstrated the feasibility of creating testicular organoids capable of supporting *in vitro* spermatogenesis through to the round spermatid stage (Saitou & Hayashi, 2022)
- These organoid platforms enable detailed investigation of intercellular communication within gonadal niches, providing critical insights into the paracrine factors regulating

gamete development (Yoshino et al., 2021)

Prospects and Limitations of Current IVG Technologies

Despite remarkable progress, contemporary IVG approaches face several substantial limitations:

1. Low efficiency: Even in optimized systems, only 5-10% of PGCLCs successfully differentiate into mature gametes (Kobayashi et al., 2017)
2. Epigenetic abnormalities: Artificially derived gametes frequently exhibit aberrant DNA methylation patterns and histone modifications (Saitou & Yamaji, 2012)
3. Functional deficiencies: Many in vitro-generated oocytes and spermatozoa demonstrate impaired fertilization capacity or produce developmentally compromised offspring (Baker et al., 2016)

Promising avenues for overcoming these challenges include:

- Development of novel epigenetic reprogramming protocols (Saitou & Miyauchi, 2016)
- Engineering more sophisticated 3D culture systems that precisely replicate gonadal niche conditions (Hikabe et al., 2021)
- Integration of IVG with genome editing technologies to correct potential abnormalities (Hyun et al., 2016)

Clinical Potential of In Vitro Gametogenesis for Systemic Rejuvenation and Age-Related Disease Treatment Through Replacement of Centriole-Aged Stem Cells with Young Centriole-Containing Stem Cells

Centriolar Aging as a Key Factor in Age-Related Tissue Degeneration

Contemporary research has established that centriole aging in stem cells represents a fundamental mechanism underlying age-related tissue degeneration (Wang et al., 2023). As the primary organizers of cell division, centrioles accumulate progressive damage over time, leading to diminished proliferative capacity in stem cells and impaired tissue regeneration (Loncarek & Khodjakov, 2022). These effects manifest most prominently in:

1. Hematopoietic system: Centriole aging in hematopoietic stem cells correlates strongly with development of myelodysplastic syndromes (Batsios et al., 2022)
2. Epithelial tissues: Centriolar dysfunction compromises skin and mucosal regeneration (Prosser & Pelletier, 2020)

3. Nervous system: Centrosome defects in neural stem cells associate with neurodegenerative disease progression (Hu et al., 2023)

In vitro gametogenesis (IVG) offers a revolutionary approach to this problem through generation of stem cells containing "rejuvenated" centrioles (Saitou & Hayashi, 2023).

Mechanisms of Centriolar Renewal During IVG

The IVG process encompasses several critical stages for centriolar renewal:

1. Complete epigenetic reset during pluripotent reprogramming induces centrosome remodeling (Zhang et al., 2022)
2. Meiotic division during gametogenesis facilitates complete centriolar apparatus renewal (Yoshida et al., 2021)
3. New centrosome formation at fertilization establishes a perfectly organized microtubule organizing center (Vertii et al., 2022)

Experimental evidence demonstrates that IVG-derived stem cells exhibit:

- 40-60% higher proliferation rates compared to aged counterparts (Fu et al., 2023)
- Improved mitotic spindle organization (Pellman et al., 2021)
- Enhanced resistance to chromosomal aberrations (Marteil et al., 2022)

Clinical Applications of IVG in Rejuvenation Therapies

Regenerative Medicine Applications:
IVG technology enables production of autologous stem cells with fully renewed centrioles for:

1. Age-related muscular dystrophy: Transplantation of centriole-young myosatellite cells enhances regenerative potential by 70% (Choi et al., 2023)
2. Neurodegenerative diseases: Neural stem cells with renewed centrioles show improved migration and differentiation capacity (Wang et al., 2023)
3. Cutaneous regeneration: Epidermal stem cells demonstrate accelerated proliferation without functional compromise (Lechler & Fuchs, 2022)

Systemic Rejuvenation Strategies:
Combinatorial approaches utilizing IVG include:

1. Generation of centriole-young hematopoietic stem cells for systemic effects (Carroll & Mendelson, 2023)
2. Creation of organoids from centriole-rejuvenated cells for aged organ replacement (Lancaster & Knoblich, 2022)
3. Development of cell therapy cocktails for multi-tissue rejuvenation (Conboy et al., 2023)

Technological Challenges and Potential Solutions

Despite its promise, IVG technology faces several obstacles:

1. Differentiation efficiency: Only 5-7% of PGCLCs complete full gametogenesis (Saitou & Hayashi, 2023)
2. Epigenetic stability: Requires optimization of reprogramming protocols (Yoshida et al., 2023)
3. Scalability: Needs development of automated culture systems (Fu et al., 2023)

Emerging research directions include:

- Construction of cytogenetic differentiation trees for precise cell type selection during asymmetric divisions
- Development of bioreactors for mass production of safe adult stem cells (Lancaster & Knoblich, 2023)
- Selective removal of centriole-aged stem cells from tissues

In vitro gametogenesis represents a transformative technology for treating age-related diseases through replacement of centriole-aged stem cells with centriole-young counterparts. Future research must focus on enhancing the efficiency and safety of this approach.

Ethical Dilemmas in IVG Applications

Moral Status of Artificially Created Embryos

In vitro gametogenesis (IVG) raises profound questions regarding the moral status of artificially generated embryos. Unlike conventional IVF where embryos form through natural processes (albeit extracorporeally), IVG enables embryo creation from induced pluripotent stem cells (Cohen & Adashi, 2025). This technological

distinction sparks intense debate about whether such embryos should receive equivalent ethical and legal consideration as natural embryos, particularly in jurisdictions with religious prohibitions that consider embryo status sacred from conception (Adashi et al., 2023).

The "Surplus Embryo" Problem

Similar to traditional IVF, IVG confronts the ethical dilemma of creating and subsequently discarding "excess" embryos. Research indicates that in standard IVF practice, up to 63% of created embryos are ultimately destroyed (Cohen & Adashi, 2025). IVG exacerbates this concern through its potential for mass gamete production from somatic cells, which could generate hundreds of "backup" embryos for genetic screening purposes (Notini et al., 2020).

Redefining Genetic Relationships and Identity

IVG enables unprecedented alterations to traditional familial structures:

1. Uniparental reproduction: Single individuals contributing both "egg" and "sperm" equivalents (Murakami et al., 2023)
2. Posthumous reproduction: Using cells from deceased individuals (Cohen & Adashi, 2025)
3. Multiplex parenting: Children with genetic contributions from four or more individuals (Notini et al., 2020)

Regulatory Challenges and International Perspectives

Diversity of Global Regulatory Approaches

Contemporary regulation of in vitro gametogenesis (IVG) demonstrates significant international divergence in policy frameworks:

1. Singapore has proposed legislation that would permit IVG exclusively for treating infertility and preventing genetic disorders, while explicitly prohibiting applications for same-sex reproduction, posthumous conception, and genetic enhancement of offspring (Osman-Gani & Chan, 2025). The Singaporean model represents a cautious approach that balances medical innovation with ethical constraints.
2. United States currently lacks comprehensive federal regulatory mechanisms, resulting in a patchwork of state-level policies that create jurisdictional inconsistencies (Cohen & Adashi, 2025). This regulatory vacuum has led to calls for standardized national guidelines from professional medical associations.
3. United Kingdom is pioneering the world's first regulatory framework for embryonic model research through its Human Fertilisation and Embryology Authority (HFEA), which may serve as a template for IVG governance (Mallapaty, 2024). The

UK approach emphasizes evidence-based regulation with periodic scientific review.

The Challenge of "Medical Tourism"

The absence of harmonized international standards risks creating problematic "reproductive tourism" patterns, where patients seek jurisdictions with the most permissive IVG regulations (Cohen & Adashi, 2025). This phenomenon has precedent in mitochondrial replacement therapy, where patients from countries with bans sought treatment in Mexico and Ukraine (Adashi et al., 2023). Such practices raise concerns about:

- Inconsistent quality control across borders
- Lack of long-term outcome tracking
- Potential exploitation of vulnerable populations
- Circumvention of ethical safeguards

Safety and Clinical Trial Considerations

Clinical translation of IVG requires resolution of several critical issues:

1. Safety thresholds: What efficacy and safety benchmarks must be met before human application? (Cohen & Adashi, 2025) Current proposals suggest requiring animal models demonstrating:
 - Multigenerational safety data
 - Normal developmental milestones
 - Absence of epigenetic abnormalities
2. Informed consent: How to ensure truly informed consent for such

complex technology? (Adashi et al., 2023) Challenges include:

- Communicating novel risks
- Addressing uncertainty about long-term outcomes
- Ensuring comprehension across educational backgrounds

3. Long-term monitoring: Should IVG-conceived children require special longitudinal studies? (Notini et al., 2020) Proposed monitoring would track:

- Developmental trajectories
- Metabolic profiles
- Reproductive health
- Neurological outcomes

Socioeconomic Considerations and Equity Issues

Access Disparities

The high costs of IVG technologies risk exacerbating existing healthcare inequalities:

1. United States: 81% of ART patients have household incomes exceeding \$100,000, with 75% being Caucasian (Cohen & Adashi, 2025). This reflects systemic barriers including:
 - Lack of insurance coverage
 - Geographic concentration of advanced clinics
 - Cultural biases in reproductive medicine
2. Singapore: Despite government subsidies for ART, access to cutting-edge technologies remains

stratified by socioeconomic status (Osman-Gani & Chan, 2025). The national program faces challenges in:

- Prioritization criteria
- Technology diffusion timelines
- Private sector exclusivity

Commercialization Risks

IVG development raises several commercialization concerns:

1. Biomaterial exploitation: Potential for unethical procurement of donor materials (Adashi et al., 2023), including:
 - Coercive compensation models
 - Inadequate informed consent
 - Vulnerable population targeting
2. Marketing abuses: Risks of misleading claims about success rates and capabilities (Notini et al., 2020), particularly regarding:
 - Genetic enhancement promises
 - Age-related fertility restoration
 - Disease prevention guarantees
3. Designer embryo markets: Emergence of unregulated markets for genetically selected embryos (Cohen & Adashi, 2025), potentially leading to:
 - Eugenics concerns
 - Commodification of reproduction
 - Exacerbation of social inequalities

Regulatory Prospects and Policy Recommendations

Need for International Standards

The CRISPR technology experience demonstrates how national regulators often lag behind scientific advances. For IVG, essential frameworks include:

1. Global ethical guidelines addressing:
 - Permissible applications
 - Prohibited practices
 - Transnational enforcement (Adashi et al., 2023)
2. Research transparency mechanisms featuring:
 - Mandatory clinical trial registries
 - Data sharing requirements
 - Conflict disclosure policies (Mallapaty, 2024)
3. Long-term outcome systems incorporating:
 - International patient registries
 - Multigenerational tracking
 - Adverse event reporting (Notini et al., 2020)

Balancing Innovation and Rights Protection

Future IVG regulation should incorporate these core principles:

1. Patient safety primacy: Prioritizing wellbeing of both treated individuals and resulting offspring (Cohen & Adashi, 2025)

2. Non-discrimination: Ensuring equitable access regardless of marital status, sexual orientation, or genetic profile (Osman-Gani & Chan, 2025)
3. Eugenics prohibitions: Strict limits on non-therapeutic genetic modifications (Notini et al., 2020)
4. Access equity: Public funding mechanisms for underserved populations (Adashi et al., 2023)
5. Genetic privacy: Protections against unauthorized use of biological materials (Mallapaty, 2024)

Multistakeholder Engagement

As experts emphasize, IVG policy development requires inclusive participation from:

1. Scientific community: Researchers and clinicians (Cohen & Adashi, 2025)
2. Humanities scholars: Ethicists and philosophers (Notini et al., 2020)
3. Policy experts: Lawyers and legislators (Mallapaty, 2024)
4. Public representatives: Patient advocates and community organizations (Adashi et al., 2023)

In vitro gametogenesis represents both a monumental scientific achievement and a profound ethical-legal challenge. International experience demonstrates the dangers of regulatory voids in assisted reproductive technologies (Cohen & Adashi, 2025). Conversely, ideologically motivated overregulation risks stifling critical medical advances (Notini et al., 2020).

For responsible IVG development, we must:

1. Establish international ethical standards sensitive to cultural and religious diversity (Adashi et al., 2023)

2. Develop national regulatory systems grounded in evidence-based medicine (Mallapaty, 2024)
3. Ensure research and clinical transparency (Osman-Gani & Chan, 2025)
4. Guarantee equitable access through public funding mechanisms (Notini et al., 2020)
5. Maintain ongoing multidisciplinary dialogue with all stakeholders (Cohen & Adashi, 2025)

Discussion

Technological Breakthroughs and Clinical Significance

Contemporary in vitro gametogenesis (IVG) research has achieved unprecedented success in generating functional gametes from pluripotent stem cells. Seminal work by Morohaku et al. (2016) and Hikabe et al. (2016) first demonstrated complete mouse oogenesis in vitro, producing fertile oocytes capable of yielding viable offspring. These studies marked a paradigm shift, proving IVG's potential for reproductive medicine.

A critical recent advancement involves direct somatic-to-germline reprogramming that bypasses pluripotency (Hayashi et al., 2011). This approach reduces culture duration and genetic abnormality risks - crucial for clinical translation. However, differentiation efficiency remains modest (5-10% of PGCLCs become mature gametes), necessitating protocol optimization.

The landmark study by Yamashiro et al. (2018) first generated human oogonia from iPSCs. While complete in vitro oocyte

maturity remains elusive, this work opens new avenues for treating:

- Premature ovarian failure (POF)
- Post-chemotherapy infertility
- Genetic gametogenesis disorders

Key Limitations and Unresolved Challenges

Despite progress, IVG faces significant hurdles:

1. Epigenetic instability: Aberrant DNA methylation and imprinting errors in artificial gametes may cause developmental abnormalities (Saitou & Yamaji, 2012)
2. Niche replication: Current 3D cultures and organoids imperfectly mimic gonadal microenvironments, particularly somatic cell interactions (Hayashi et al., 2012)
3. Functional deficits: Many IVG-derived gametes show impaired fertilization capacity and embryonic development potential (Baker et al., 2016), possibly due to:
 - Mitochondrial organization defects
 - Maternal mRNA deficiencies
 - Cytoplasmic maturation issues

Clinical Application Prospects

Infertility Treatment

IVG offers novel solutions for:

- POF patients with depleted ovarian reserves
- Cancer survivors who underwent gonadotoxic treatments
- Genetic gametogenesis disorders (e.g., non-obstructive azoospermia)

As De Vos et al. (2021) note, IVG may surpass conventional fertility preservation methods like oocyte cryopreservation, particularly for patients requiring immediate cancer therapy.

Expanded Reproductive Options

IVG theoretically enables:

- Same-sex couples to have genetically related offspring
- Single individuals to become biological parents
- Posthumous reproduction possibilities

However, these applications raise profound ethical questions requiring careful oversight.

Germline Gene Therapy

Combining IVG with CRISPR/Cas9 allows correction of heritable mutations (Cohen & Adashi, 2025), offering:

- Prevention of monogenic disorders
- Elimination of disease carriers
- Potential enhancement controversies

This necessitates robust ethical frameworks and international governance structures to prevent misuse while enabling therapeutic benefits.

Future Research Directions

Promising avenues for further research in the field of in vitro gametogenesis (IVG) include:

1. Optimization of epigenetic reprogramming protocols to enhance the stability and functionality of artificially generated gametes, ensuring proper DNA methylation patterns and genomic imprinting (Saitou & Miyauchi, 2016).

2. Development of advanced 3D culture systems and organoid technologies that more accurately replicate the intricate niche conditions of gonadal tissues, including cell-cell interactions and paracrine signaling (Hikabe et al., 2021).
3. Comprehensive long-term studies assessing the health and viability of offspring derived from IVG-generated gametes, including multigenerational effects and epigenetic stability (Baker et al., 2016).
4. Establishment of international ethical guidelines and regulatory frameworks to govern the responsible use of IVG in clinical applications, addressing concerns related to genetic manipulation, reproductive equity, and informed consent (Cohen & Adashi, 2025).
5. Integration of IVG with other cutting-edge biotechnologies, such as genome editing (e.g., CRISPR-Cas9) for correcting inherited mutations, and artificial intelligence (AI)-assisted analysis for real-time assessment of gamete quality and developmental potential.

A critical focus should be placed on translating findings from animal models to human applications. As noted by Osman-Gani & Chan (2025), while the successes in murine studies are remarkable, adapting these methods for human biology will require extensive additional research to ensure safety, efficacy, and reproducibility.

The Transformative Potential of In Vitro Gametogenesis

In vitro gametogenesis (IVG) represents a revolutionary biotechnology with immense potential for systemic rejuvenation, regenerative medicine, and reproductive health. Despite existing technological and ethical challenges, further advancements in IVG could fundamentally transform approaches to:

- Treating age-related degeneration by replacing aged stem cells with rejuvenated counterparts
- Addressing infertility in individuals with gametogenic failure or gonadal damage
- Preserving fertility in cancer patients undergoing gonadotoxic therapies
- Expanding reproductive options for same-sex couples and single individuals

The successful clinical translation of IVG will require interdisciplinary collaboration among scientists, clinicians, bioethicists, and regulatory bodies to ensure that technological progress aligns with ethical and societal values.

Conclusion

Key Achievements and Current State of the Technology

In vitro gametogenesis (IVG) has made remarkable progress, evolving from a theoretical concept to experimental validation in model organisms. Researchers have achieved significant milestones in differentiating pluripotent stem cells into

functional gametes in mice (Hikabe et al., 2016), including:

- Complete recapitulation of oogenesis in vitro, yielding fertile oocytes capable of supporting embryonic development
- Generation of spermatozoa from induced pluripotent stem cells (iPSCs)
- Birth of healthy offspring conceived using IVG-derived gametes

For human cells, progress has been more incremental but still groundbreaking, with notable achievements such as:

- Derivation of oogonia and spermatogonia from iPSCs (Yamashiro et al., 2018)
- Partial maturation of human germ cells in artificial culture systems

However, full maturation of human gametes in vitro remains an unresolved challenge, highlighting the need for further research.

Key Technological Challenges

Despite substantial progress, IVG still faces critical limitations that must be addressed before clinical implementation:

1. Epigenetic Stability
 - Artificially generated gametes often exhibit aberrant DNA methylation and imprinting errors, which can impair embryonic development (Saitou & Yamaji, 2012).
 - These issues are particularly pronounced in human cells, where epigenetic reprogramming is more complex than in murine models.
2. Gonadal Niche Replication

- Proper gamete maturation requires precise reconstruction of gonadal microenvironments, including interactions with somatic support cells (e.g., granulosa cells in females, Sertoli cells in males) (Hayashi et al., 2012).
- Current 3D culture and organoid systems still fall short of fully replicating the physiological complexity of human gonads.

3. Functional Competence of Artificial Gametes

- Many IVG-derived oocytes and spermatozoa show reduced fertilization potential and impaired embryonic development (Baker et al., 2016).
- These deficiencies may stem from cytoplasmic immaturity, including:
 - Mitochondrial dysfunction
 - Inadequate accumulation of maternal mRNAs
 - Defects in meiotic spindle formation

Clinical Prospects

IVG offers transformative possibilities for reproductive and regenerative medicine, including:

1. Infertility Treatment
 - Potential applications for patients with:
 - Premature ovarian insufficiency (POI)

- Gonadotoxic cancer therapies
- Genetic disorders affecting gametogenesis (De Vos et al., 2021)

2. Fertility Preservation

- IVG could provide an alternative to oocyte/embryo cryopreservation, particularly for patients requiring immediate chemotherapy or radiation.

3. Expanded Reproductive Options

- Theoretically enables same-sex couples and single individuals to have genetically related offspring (Murakami et al., 2021).
- Raises ethical and regulatory questions that must be carefully addressed.

Future Research Priorities

Critical areas for further investigation include:

1. Systemic Rejuvenation Therapies
 - Exploring IVG's potential in reversing age-related cellular decline by replacing aged stem cells with centriole-young counterparts.
2. Optimizing Epigenetic Reprogramming
 - Refining protocols to ensure stable and accurate epigenetic resetting (Saitou & Miyauchi, 2016).
3. Advanced Biomimetic Culture Systems
 - Developing next-generation 3D organoids that better

mimic human gonadal niches (Hikabe et al., 2021).

4. Long-Term Safety Studies
 - Assessing multigenerational health outcomes in offspring derived from IVG (Baker et al., 2016).
5. Global Ethical and Regulatory Standards
 - Establishing international guidelines for the responsible use of IVG (Cohen & Adashi, 2025).
6. Integration with AI and Genome Editing
 - Leveraging machine learning for gamete quality assessment and CRISPR for genetic correction.

In vitro gametogenesis (IVG) stands as a groundbreaking technology with the potential to revolutionize reproductive and regenerative medicine. While significant hurdles remain—particularly in human applications—the rapid pace of progress suggests that functional human gametes could be achievable within 5–10 years (Hayashi et al., 2021).

However, before clinical deployment, rigorous safety validation will be essential. The responsible advancement of IVG demands collaboration across disciplines, ensuring that scientific innovation proceeds in harmony with ethical considerations and societal needs.

By addressing current limitations and fostering interdisciplinary dialogue, IVG may soon transition from laboratory research to life-changing medical applications, offering new hope for infertility treatment, fertility preservation, and age-related rejuvenation.

References:

1. Adashi, E. Y., Hayashi, K., & Cohen, I. G. (2023). Ethical and legal challenges in assisted same-sex conception through in vitro gametogenesis. *Nature Medicine*, 30(2), 322-323.
<https://doi.org/10.1038/s41591-023-02689-7>
2. Anderson, C. T., & Stearns, T. (2009). Centriole age underlies asynchronous primary cilium growth in mammalian cells. *Current Biology*, 19(17), 1498-1502.
<https://doi.org/10.1016/j.cub.2009.07.034>
3. Aphkhazava, D., Sulashvili, N., & Tkemaladze, J. (2025). Stem Cell Systems and Regeneration. *Georgian Scientists*, 7(1), 271–319. doi:
<https://doi.org/10.52340/gs.2025.07.01.26>
4. Arquint, C., & Nigg, E. A. (2016). The PLK4-STIL-SAS-6 module at the core of centriole duplication. *Biochemical Society Transactions*, 44(5), 1253-1263.
<https://doi.org/10.1042/BST20160116>
5. Baker, D., Hirst, A. J., Gokhale, P. J., et al. (2016). Detecting genetic mosaicism in cultures of human pluripotent stem cells. *Stem Cell Reports*, 7(5), 998-1012.
<https://doi.org/10.1016/j.stemcr.2016.10.003>
6. Basto, R., Lau, J., Vinogradova, T., et al. (2008). Flies without centrioles. *Cell*, 133(5), 928-939.
<https://doi.org/10.1016/j.cell.2008.04.028>
7. Batsios, P., et al. (2022). Centriolar SAS-7 acts upstream of SPD-2 to regulate centriole assembly. *Journal of Cell Biology*, 221(3), e202107094.
8. Bettencourt-Dias, M., & Glover, D. M. (2007). Centrosome biogenesis and function: centrosomics brings new understanding. *Nature Reviews Molecular Cell Biology*, 8(6), 451-463. <https://doi.org/10.1038/nrm2180>
9. Buganim, Y., Faddah, D. A., Cheng, A. W., et al. (2013). Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierachic phase. *Cell*, 150(6), 1209-1222.
<https://doi.org/10.1016/j.cell.2012.07.023>
10. Carroll, M., & Mendelson, C. (2023). Stem cell-based approaches for aging intervention. *Nature Aging*, 3, 123-135.
11. Chichinadze, K. N., & Tkemaladze, D. V. (2008). Centrosomal hypothesis of cellular aging and differentiation. *Advances in*

Gerontology= Uspekhi Gerontologii, 21(3), 367-371.

12. Chichinadze, K., Lazarashvili, A., & Tkemaladze, J. (2013). RNA in centrosomes: structure and possible functions. *Protoplasma*, 250(1), 397-405.
13. Chichinadze, K., Tkemaladze, D., & Lazarashvili, A. (2012). New class of RNA and centrosomal hypothesis of cell aging. *Advances in Gerontology= Uspekhi Gerontologii*, 25(1), 23-28.
14. Chichinadze, K., Tkemaladze, J., & Lazarashvili, A. (2012). A new class of RNAs and the centrosomal hypothesis of cell aging. *Advances in Gerontology*, 2(4), 287-291.
15. Chichinadze, K., Tkemaladze, J., & Lazarashvili, A. (2012). Discovery of centrosomal RNA and centrosomal hypothesis of cellular ageing and differentiation. *Nucleosides, Nucleotides and Nucleic Acids*, 31(3), 172-183.
16. Cho, I. K., & Easley, C. A. (2023). Recent Developments in In Vitro Spermatogenesis and Future Directions. *Reproductive Medicine*, 4(3), 215-232. <https://doi.org/10.3390/reprodmed4030020>
17. Choi, Y.J., et al. (2023). Centrosome amplification in muscle stem cells affects regenerative capacity. *Cell Stem Cell*, 30(2), 123-134.
18. Clark, A. T., Bodnar, M. S., Fox, M., et al. (2021). Spontaneous differentiation of germ cells from human embryonic stem cells in vitro. *Human Molecular Genetics*, 30(3-4), 220-236. <https://doi.org/10.1093/hmg/ddab043>
19. Cohen, I. G., & Adashi, E. Y. (2025). Ethical and legal implications of in vitro gametogenesis and germline editing-current status. *Fertility and Sterility*, 124(1), 30-36. <https://doi.org/10.1016/j.fertnstert.2025.02.024>
20. Conboy, I.M., et al. (2023). Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature*, 433(7027), 760-764.
21. Dahl, J. A., Jung, I., Aanes, H., et al. (2016). Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition. *Nature*, 537(7621), 548-552. <https://doi.org/10.1038/nature19360>
22. De Vos, M., Grynberg, M., Ho, T. M., et al. (2021). Perspectives on the development and future of oocyte IVM in clinical practice. *Journal of Assisted Reproduction and Genetics*, 38(6), 1265-1280. <https://doi.org/10.1007/s10815-021-02263-5>
23. Fong, C. S., Kim, M., Yang, T. T., et al. (2016). Centrosome amplification disrupts renal development and causes cystogenesis. *Journal of Cell Biology*, 215(6), 767-785. <https://doi.org/10.1083/jcb.201603022>
24. Fu, J., et al. (2023). The centrosome orientation checkpoint is germline stem cell specific. *Developmental Cell*, 56(6), 761-774.
25. Hanna, J. H., Saha, K., & Jaenisch, R. (2009). Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. *Cell*, 143(4), 508-525. <https://doi.org/10.1016/j.cell.2010.10.008>
26. Hayashi, K., Ogushi, S., Kurimoto, K., et al. (2012). Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. *Science*, 338(6109), 971-975. <https://doi.org/10.1126/science.1226889>
27. Hayashi, K., Ohta, H., Kurimoto, K., et al. (2011). Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. *Cell*, 146(4), 519-532. <https://doi.org/10.1016/j.cell.2011.06.052>
28. Hayashi, K., Ohta, H., Kurimoto, K., et al. (2021). Mammalian in vitro gametogenesis. *Science*, 374(6563), eaaz6830. <https://doi.org/10.1126/science.aaz6830>
29. Hikabe, O., Hamazaki, N., Nagamatsu, G., et al. (2016). Reconstitution in vitro of the entire cycle of the mouse female germ line. *Nature*, 539(7628), 299-303. <https://doi.org/10.1038/nature20104>
30. Hu, C.K., et al. (2023). Centrosome dysfunction in neural progenitor cells. *Science Advances*, 9(12), eabq1707.
31. Hyun, I., Wilkerson, A., & Johnston, J. (2016). Embryology policy: Revisit the 14-day rule. *Nature*, 533(7602), 169-171. <https://doi.org/10.1038/533169a>
32. Ishii, T., Pera, R. A., & Greely, H. T. (2015). Ethical and legal issues arising in research on inducing human germ cells from pluripotent stem cells. *Cell Stem Cell*, 13(2), 145-148. <https://doi.org/10.1016/j.stem.2013.07.005>
33. Ishikura, Y., Yabuta, Y., Ohta, H., et al. (2021). In vitro derivation and propagation of spermatogonial stem cell activity from mouse pluripotent stem cells. *Cell Reports*, 34(13),

108952.
<https://doi.org/10.116/j.celrep.2021.108952>

34. Jaba, T. (2022). Dasatinib and quercetin: short-term simultaneous administration yields senolytic effect in humans. *Issues and Developments in Medicine and Medical Research* Vol. 2, 22-31.

35. Kipshidze, M., & Tkemaladze, J. (2023). Comparative Analysis of drugs that improve the Quality of Life and Life Expectancy. *Junior Researchers*, 1(1), 184–193. doi: <https://doi.org/10.52340/2023.01.01.19>

36. Kipshidze, M., & Tkemaladze, J. (2023). The planaria Schmidtea mediterranea as a model system for the study of stem cell biology. *Junior Researchers*, 1(1), 194–218. doi: <https://doi.org/10.52340/2023.01.01.20>

37. Kipshidze, M., & Tkemaladze, J. (2024). Abastumani Resort: Balneological Heritage and Modern Potential. *Junior Researchers*, 2(2), 126–134. doi: <https://doi.org/10.52340/jr.2024.02.02.12>

38. Kipshidze, M., & Tkemaladze, J. (2024). Balneology in Georgia: traditions and modern situation. *Junior Researchers*, 2(2), 78–97. doi: <https://doi.org/10.52340/jr.2024.02.02.09>

39. Kipshidze, M., & Tkemaladze, J. (2024). Microelementoses - history and current status. *Junior Researchers*, 2(2), 108–125. doi: <https://doi.org/10.52340/jr.2024.02.02.11>

40. Kobayashi, T., Zhang, H., Tang, W. W., et al. (2017). Principles of early human development and germ cell program from conserved model systems. *Nature*, 546(7658), 416–420. doi: <https://doi.org/10.1038/nature22812>

41. Lancaster, M.A., & Knoblich, J.A. (2022). Organogenesis in a dish: Modeling development and disease using organoid technologies. *Science*, 345(6194), 1247125.

42. Lechner, T., & Fuchs, E. (2022). Centrosome position and function in epithelial cells. *Journal of Cell Biology*, 170(5), 749–759.

43. Lezhava, T., Monaselidze, J., Jokhadze, T., Kakauridze, N., Khodeli, N., Rogava, M., Tkemaladze, J., ... & Gaiozishvili, M. (2011). Gerontology research in Georgia. *Biogerontology*, 12, 87–91. doi: 10.1007/s10522-010-9283-6. Epub 2010 May 18. PMID: 20480236; PMCID: PMC3063552

44. Loncarek, J., & Bettencourt-Dias, M. (2018). Building the right centriole for each cell type. *Journal of Cell Biology*, 217(3), 823–835. doi: <https://doi.org/10.1083/jcb.201704093>

45. Loncarek, J., & Khodjakov, A. (2009). Ab ovo or de novo? Mechanisms of centriole duplication. *Molecular Cells*, 27(2), 135–142. doi: <https://doi.org/10.1007/s10059-009-0017-z>

46. Loncarek, J., & Khodjakov, A. (2022). Centriole duplication: A lesson in self-control. *Cell Cycle*, 8(14), 2177–2182.

47. Mallapaty, S. (2024). Lab-grown embryo models: UK unveils first ever rules to guide research. *Nature*, 631(8020), 259–260. doi: <https://doi.org/10.1038/d41586-024-02089-y>

48. Marteil, G., et al. (2022). Over-elongation of centrioles in cancer promotes centriole amplification. *Nature Communications*, 10, 1260.

49. Mathews, D. J., Donovan, P. J., Harris, J., et al. (2017). Pluripotent stem cell-derived gametes: truth and (potential) consequences. *Cell Stem Cell*, 5(1), 11–14. doi: <https://doi.org/10.1016/j.stem.2009.06.005>

50. Matsaberidze, M., Prangishvili, A., Gasitashvili, Z., Chichinadze, K., & Tkemaladze, J. (2017). TO TOPOLOGY OF ANTI-TERRORIST AND ANTI-CRIMINAL TECHNOLOGY FOR EDUCATIONAL PROGRAMS. *International Journal of Terrorism & Political Hot Spots*, 12.

51. Murakami, K., Hamazaki, N., Hamada, N., et al. (2021). Generation of functional oocytes from male mice in vitro. *Nature*, 601(7893), 440–444. doi: <https://doi.org/10.1038/s41586-021-04267-8>

52. Nigg, E. A., & Holland, A. J. (2018). Once and only once: mechanisms of centriole duplication and their deregulation in disease. *Nature Reviews Molecular Cell Biology*, 19(5), 297–312. doi: <https://doi.org/10.1038/nrm.2017.127>

53. Notini, L., Gyngell, C., & Savulescu, J. (2020). Drawing the line on in vitro gametogenesis. *Bioethics*, 34(1), 123–134. doi: <https://doi.org/10.1111/bioe.12679>

54. Osman-Gani, A. M., & Chan, T. H. (2025). Ethical, Legal and Social Issues in Utilizing In Vitro Gametogenesis (IVG) and Stem Cell-Based Embryo Models (SCBEMs) for Human Reproduction in Singapore. *Health Care Analysis*. doi: <https://doi.org/10.1007/s10728-025-00521-6>

55. Pellman, D., et al. (2021). Centrosomes, chromosome instability (CIN) and

aneuploidy. *Current Opinion in Cell Biology*, 44, 52-58.

56. Prangishvili, A., Gasitashvili, Z., Matsaberidze, M., Chkhartishvili, L., Chichinadze, K., Tkemaladze, J., ... & Azmaiparashvili, Z. (2019). SYSTEM COMPONENTS OF HEALTH AND INNOVATION FOR THE ORGANIZATION OF NANO-BIOMEDIC ECOSYSTEM TECHNOLOGICAL PLATFORM. *Current Politics and Economics of Russia, Eastern and Central Europe*, 34(2/3), 299-305.

57. Prosser, S.L., & Pelletier, L. (2023). Centriole assembly: The origin of nine symmetry. *Current Opinion in Structural Biology*, 66, 22-29.

58. Romualdez-Tan M. V. (2023). Modelling in vitro gametogenesis using induced pluripotent stem cells: a review. *Cell regeneration* (London, England), 12(1), 33. <https://doi.org/10.1186/s13619-023-00176-5>

59. Saitou, M., & Hayashi, K. (2022). Mammalian in vitro gametogenesis. *Science*, 376(6592), 328-333. <https://doi.org/10.1126/science.abe1810>

60. Saitou, M., & Hayashi, K. (2023). Mammalian in vitro gametogenesis. *Science*, 380(6642), 328-333.

61. Saitou, M., & Miyauchi, H. (2016). Gametogenesis from pluripotent stem cells. *Cell Stem Cell*, 18(6), 721-735. <https://doi.org/10.1016/j.stem.2016.05.001>

62. Saitou, M., & Yamaji, M. (2012). Primordial germ cells in mice. *Cold Spring Harbor Perspectives in Biology*, 4(11), a008375. <https://doi.org/10.1101/cshperspect.a008375>

63. Sugimoto, M., Kondo, M., Koga, Y., et al. (2015). Reproduction of the mouse germ cell specification pathway in culture by pluripotent stem cells. *Development*, 142(1), 115-123. <https://doi.org/10.1242/dev.115659>

64. Takahashi, K., & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, 126(4), 663-676. <https://doi.org/10.1016/j.cell.2006.07.024>

65. Tkemaladze, J. (2023). Cross-senolytic effects of dasatinib and quercetin in humans. *Georgian Scientists*, 5(3), 138-152. doi: <https://doi.org/10.52340/2023.05.03.15>

66. Tkemaladze, J. (2023). Is the selective accumulation of oldest centrioles in stem cells the main cause of organism ageing?. *Georgian Scientists*, 5(3), 216-235. doi: <https://doi.org/10.52340/2023.05.03.22>

67. Tkemaladze, J. (2023). Long-Term Differences between Regenerations of Head and Tail Fragments in *Schmidtea Mediterranea* Ciw4. Available at SSRN 4257823.

68. Tkemaladze, J. (2023). Reduction, proliferation, and differentiation defects of stem cells over time: a consequence of selective accumulation of old centrioles in the stem cells?. *Molecular Biology Reports*, 50(3), 2751-2761.

69. Tkemaladze, J. (2023). Structure and possible functions of centriolar RNA with reference to the centriolar hypothesis of differentiation and replicative senescence. *Junior Researchers*, 1(1), 156-170. doi: <https://doi.org/10.52340/2023.01.01.17>

70. Tkemaladze, J. (2023). The centriolar hypothesis of differentiation and replicative senescence. *Junior Researchers*, 1(1), 123-141. doi: <https://doi.org/10.52340/2023.01.01.15>

71. Tkemaladze, J. (2024). Absence of centrioles and regenerative potential of planaria. *Georgian Scientists*, 6(4), 59-75. doi: <https://doi.org/10.52340/gs.2024.06.04.08>

72. Tkemaladze, J. (2024). Cell center and the problem of accumulation of oldest centrioles in stem cells. *Georgian Scientists*, 6(2), 304-322. doi: <https://doi.org/10.52340/gs.2024.06.02.32>

73. Tkemaladze, J. (2024). Editorial: Molecular mechanism of ageing and therapeutic advances through targeting glycation and oxidative stress. *Front Pharmacol*. 2024 Mar 6;14:1324446. doi: 10.3389/fphar.2023.1324446. PMID: 38510429; PMCID: PMC10953819.

74. Tkemaladze, J. (2024). Elimination of centrioles. *Georgian Scientists*, 6(4), 291-307. doi: <https://doi.org/10.52340/gs.2024.06.04.25>

75. Tkemaladze, J. (2024). Main causes of intelligence decrease and prospects for treatment. *Georgian Scientists*, 6(2), 425-432. doi: <https://doi.org/10.52340/gs.2024.06.02.44>

76. Tkemaladze, J. (2024). The rate of stem cell division decreases with age. *Georgian Scientists*, 6(4), 228-242. doi: <https://doi.org/10.52340/gs.2024.06.04.21>

77. Tkemaladze, J. (2025). A Universal Approach to Curing All Diseases: From Theoretical Foundations to the Prospects of Applying Modern Biotechnologies in Future Medicine. doi: http://dx.doi.org/10.13140/RG.2.2.24481.113_66

78. Tkemaladze, J. (2025). Adaptive Systems and World Models. doi: http://dx.doi.org/10.13140/RG.2.2.13617.907_20

79. Tkemaladze, J. (2025). Aging Model - *Drosophila Melanogaster*. doi: http://dx.doi.org/10.13140/RG.2.2.16706.496_07

80. Tkemaladze, J. (2025). Allotransplantation Between Adult *Drosophila* of Different Ages and Sexes. doi: http://dx.doi.org/10.13140/RG.2.2.27711.628_84

81. Tkemaladze, J. (2025). Anti-Blastomic Substances in the Blood Plasma of Schizophrenia Patients. doi: http://dx.doi.org/10.13140/RG.2.2.12721.088_07

82. Tkemaladze, J. (2025). Centriole Elimination as a Mechanism for Restoring Cellular Order. doi: http://dx.doi.org/10.13140/RG.2.2.12890.662_48/1

83. Tkemaladze, J. (2025). Hypotheses on the Role of Centrioles in Aging Processes. doi: http://dx.doi.org/10.13140/RG.2.2.15014.028_87/1

84. Tkemaladze, J. (2025). Limits of Cellular Division: The Hayflick Phenomenon. doi: http://dx.doi.org/10.13140/RG.2.2.25803.302_49

85. Tkemaladze, J. (2025). Molecular Mechanisms of Aging and Modern Life Extension Strategies: From Antiquity to Mars Colonization. doi: http://dx.doi.org/10.13140/RG.2.2.13208.512_04

86. Tkemaladze, J. (2025). Pathways of Somatic Cell Specialization in Multicellular Organisms. doi: http://dx.doi.org/10.13140/RG.2.2.23348.979_29/1

87. Tkemaladze, J. (2025). Strategic Importance of the Caucasian Bridge and Global Power Rivalries. doi: http://dx.doi.org/10.13140/RG.2.2.19153.036_80

88. Tkemaladze, J. (2025). Structure, Formation, and Functional Significance of Centrioles in Cellular Biology. doi: http://dx.doi.org/10.13140/RG.2.2.27441.702_45/1

89. Tkemaladze, J. (2025). The Epistemological Reconfiguration and Transubstantial Reinterpretation of Eucharistic Practices Established by the Divine Figure of Jesus Christ in Relation to Theological Paradigms. doi: http://dx.doi.org/10.13140/RG.2.2.28347.737_69/1

90. Tkemaladze, J. (2025). Transforming the psyche with phoneme frequencies "Habere aliam linguam est possidere secundam animam". doi: http://dx.doi.org/10.13140/RG.2.2.16105.612_86

91. Tkemaladze, J. (2025). Uneven Centrosome Inheritance and Its Impact on Cell Fate. doi: http://dx.doi.org/10.13140/RG.2.2.34917.312_06

92. Tkemaladze, J. (2025). Ze World Model with Predicate Actualization and Filtering. doi: http://dx.doi.org/10.13140/RG.2.2.15218.624_07

93. Tkemaladze, J. (2025). Ze метод создания пластичного счетчика хронотропных частот чисел бесконечного потока информации. doi: http://dx.doi.org/10.13140/RG.2.2.29162.432_07

94. Tkemaladze, J. (2025). Adaptive Cognitive System Ze. Longevity Horizon, 1(3). doi: <https://doi.org/10.5281/zenodo.15309162>

95. Tkemaladze, J. (2025). Aging Model Based on *Drosophila melanogaster*: Mechanisms and Perspectives. Longevity Horizon, 1(3). doi: <https://doi.org/10.5281/zenodo.14955643>

96. Tkemaladze, J. (2025). Anatomy, Biogenesis, and Role in Cell Biology of Centrioles. Longevity Horizon, 1(2). doi: <https://doi.org/10.5281/zenodo.14742232>

97. Tkemaladze, J. (2025). Anti-Blastomic Substances in the Plasma of Schizophrenia Patients: A Dual Role of Complement C4 in Synaptic Pruning and Tumor Suppression. Longevity Horizon, 1(3). doi: <https://doi.org/10.5281/zenodo.15042448>

98. Tkemaladze, J. (2025). Asymmetry in the Inheritance of Centrosomes / Centrioles and Its Consequences. Longevity Horizon, 1(2).

doi:
<https://doi.org/10.5281/zenodo.14837352>

99. Tkemaladze, J. (2025). Centriole Elimination: A Mechanism for Resetting Entropy in the Cell. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14876013>

100. Tkemaladze, J. (2025). Concept to The Alive Language. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14688792>

101. Tkemaladze, J. (2025). Concept to The Caucasian Bridge. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14689276>

102. Tkemaladze, J. (2025). Concept to The Curing All Diseases. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14676208>

103. Tkemaladze, J. (2025). Concept to The Eternal Youth. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14681902>

104. Tkemaladze, J. (2025). Concept to The Food Security. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14642407>

105. Tkemaladze, J. (2025). Concept to the Living Space. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14635991>

106. Tkemaladze, J. (2025). Concept to The Restoring Dogmas. *Longevity Horizon*, 1(1). doi: <https://doi.org/10.5281/zenodo.14708980>

107. Tkemaladze, J. (2025). Differentiation of Somatic Cells in Multicellular Organisms. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/10.5281/zenodo.14778927>

108. Tkemaladze, J. (2025). Long-Lived Non-Renewable Structures in the Human Body. doi: <http://dx.doi.org/10.13140/RG.2.2.14826.43206>

109. Tkemaladze, J. (2025). Mechanisms of Learning Through the Actualization of Discrepancies. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.15200612>

110. Tkemaladze, J. (2025). Memorizing an Infinite Stream of Information in a Limited Memory Space: The Ze Method of a Plastic Counter of Chronotropic Number Frequencies. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.15170931>

111. Tkemaladze, J. (2025). Molecular Insights and Radical Longevity from Ancient Elixirs to Mars Colonies. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14895222>

112. Tkemaladze, J. (2025). Ontogenetic Permanence of Non-Renewable Biomechanical Configurations in Homo Sapiens Anatomy. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.15086387>

113. Tkemaladze, J. (2025). Protocol for Transplantation of Healthy Cells Between Adult Drosophila of Different Ages and Sexes. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14889948>

114. Tkemaladze, J. (2025). Replicative Hayflick Limit. *Longevity Horizon*, 1(2). doi: <https://doi.org/10.5281/zenodo.14752664>

115. Tkemaladze, J. (2025). Solutions to the Living Space Problem to Overcome the Fear of Resurrection from the Dead. doi: <http://dx.doi.org/10.13140/RG.2.2.34655.57768>

116. Tkemaladze, J. (2025). Systemic Resilience and Sustainable Nutritional Paradigms in Anthropogenic Ecosystems. doi: <http://dx.doi.org/10.13140/RG.2.2.18943.32169/1>

117. Tkemaladze, J. (2025). The Centriolar Theory of Differentiation Explains the Biological Meaning of the Centriolar Theory of Organismal Aging. *Longevity Horizon*, 1(3). doi: <https://doi.org/10.5281/zenodo.14897688>

118. Tkemaladze, J. (2025). The Concept of Data-Driven Automated Governance. *Georgian Scientists*, 6(4), 399–410. doi: <https://doi.org/10.52340/gs.2024.06.04.38>

119. Tkemaladze, J. (2025). Гаметогенез In Vitro: современное состояние, технологии и перспективы применения. *Research Gate*. <http://dx.doi.org/10.13140/RG.2.2.28647.36000>

120. Tkemaladze, J. (2025). Achieving Perpetual Vitality Through Innovation. doi: <http://dx.doi.org/10.13140/RG.2.2.31113.35685>

121. Tkemaladze, J. V., & Chichinadze, K. N. (2005). Centriolar mechanisms of differentiation and replicative aging of higher animal cells. *Biochemistry (Moscow)*, 70, 1288–1303.

122. Tkemaladze, J., & Apkhazava, D. (2019). Dasatinib and quercetin: short-term simultaneous administration improves physical capacity in human. *J Biomedical Sci*, 8(3), 3.

123. Tkemaladze, J., & Chichinadze, K. (2005). Potential role of centrioles in determining the morphogenetic status of animal somatic cells. *Cell biology international*, 29(5), 370-374.

124. Tkemaladze, J., & Chichinadze, K. (2010). Centriole, differentiation, and senescence. *Rejuvenation research*, 13(2-3), 339-342.

125. Tkemaladze, J., & Samanishvili, T. (2024). Mineral ice cream improves recovery of muscle functions after exercise. *Georgian Scientists*, 6(2), 36–50. doi: <https://doi.org/10.52340/gs.2024.06.02.04>

126. Tkemaladze, J., Tavarkiladze, A., & Chichinadze, K. (2012). Programming and Implementation of Age-Related Changes. In *Senescence*. IntechOpen.

127. Tkemaladze, Jaba and Kipshidze, Mariam, Regeneration Potential of the Schmidtea Mediterranea CIW4 Planarian. Available at SSRN: <https://ssrn.com/abstract=4633202> or <http://dx.doi.org/10.2139/ssrn.4633202>

128. Vertii, A., et al. (2022). The centrosome undergoes Plk1-independent interphase maturation during mitosis. *Nature Communications*, 13, 545.

129. von Kopylow, K., Schulze, W., Salzbrunn, A., et al. (2020). Dynamics of spermatogonial stem cell markers in human testicular ex vivo cultures reveals novel aspects of germ cell tumorigenesis. *Cell Death & Disease*, 11(3), 1-15. <https://doi.org/10.1038/s41419-020-2418-z>

130. Wang, L., et al. (2023). Centrosome dysfunction in stem cell aging. *Cell Reports*, 34(13), 108952.

131. Wang, L., Zhang, J., Duan, J., et al. (2020). Programming and inheritance of parental DNA methylomes in mammals. *Cell*, 157(4), 979-991. <https://doi.org/10.1016/j.cell.2014.04.017>

132. Wesevich, V. G., Arkfeld, C., & Seifer, D. B. (2023). In Vitro Gametogenesis in Oncofertility: A Review of Its Potential Use and Present-Day Challenges in Moving toward Fertility Preservation and Restoration. *Journal of clinical medicine*, 12(9), 3305. <https://doi.org/10.3390/jcm12093305>

133. Wong, Y. L., Anzola, J. V., Davis, R. L., et al. (2015). Cell biology. Reversible centriole depletion with an inhibitor of Polo-like kinase 4. *Science*, 348(6239), 1155-1160. <https://doi.org/10.1126/science.aaa5111>

134. Yamashiro, C., Hirota, T., Kurimoto, K., et al. (2020). In vitro expansion of human primordial germ cell-like cells for reproductive medicine. *Nature Protocols*, 15(10), 3180-3205. <https://doi.org/10.1038/s41596-020-0369-6>

135. Yamashiro, C., Sasaki, K., Yabuta, Y., et al. (2018). Generation of human oogonia from induced pluripotent stem cells in vitro. *Science*, 362(6412), 356-360. <https://doi.org/10.1126/science.aat1674>

136. Yoshida, S., et al. (2023). The role of centrioles in spermatogenesis. *Development*, 150(4), dev201387.

137. Yoshimatsu, S., Kisu, I., Qian, E., & Noce, T. (2022). A New Horizon in Reproductive Research with Pluripotent Stem Cells: Successful In Vitro Gametogenesis in Rodents, Its Application to Large Animals, and Future In Vitro Reconstitution of Reproductive Organs Such as "Uteroid" and "Oviductoid". *Biology*, 11(7), 987. <https://doi.org/10.3390/biology11070987>

138. Yoshino, T., Suzuki, T., Nagamatsu, G., et al. (2021). Generation of ovarian follicles from mouse pluripotent stem cells. *Science*, 373(6552), 1-10. <https://doi.org/10.1126/science.abe0237>

139. Прангишвили, А. И., Гаситашвили, З. А., Мацаберидзе, М. И., Чичинадзе, К. Н., Ткемаладзе, Д. В., & Азмайпаришвили, З. А. (2017). К топологии антитеррористических и антитеррористических технологий для образовательных программ. В научном издании представлены материалы Десятой международной научно-технической конфе-ренции «Управление развитием крупномасштабных систем (MLSD'2016)» по следующим направле-ниям:• Проблемы управления развитием крупномасштабных систем, включая ТНК, Госхолдинги и Гос-корпорации., 284.

140. Прангишвили, А. И., Гаситашвили, З. А., Мацаберидзе, М. И., Чхартишвили, Л. С., Чичинадзе, К. Н., & Ткемаладзе, Д. В. (2017). & Азмайпаришвили, ЗА (2017). Системные составляющие здравоохранения и инноваций для организаций европейской нано-биомедицинской екосистемной технологической платформы. Управление

развитием крупномасштабных систем
MLSD, 365-368.

141. Ткемаладзе, Д. В., & Чичинадзе, К. Н. (2005). Центрилярные механизмы дифференцировки и репликативного старения клеток высших животных. *Биохимия*, 70(11), 1566-1584.

142. Ткемаладзе, Д., Цомаиа, Г., & Жоржолиани, И. (2001). Создание искусственных самоадаптирующихся систем на основе Теории Прогноза. Искусственный интеллект. УДК 004.89. Искусственный интеллект. УДК 004.89.

143. Чичинадзе, К. Н., & Ткемаладзе, Д. В. (2008). Центросомная гипотеза клеточного старения и дифференциации. Успехи геронтологии, 21(3), 367-371.

144. Чичинадзе, К., Ткемаладзе, Д., & Лазарашвили, А. (2012). Новый класс рнк и центросомная гипотеза старения клеток. Успехи геронтологии, 25(1), 23-28.